Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10897645 | 0.88 | TDP1 (0.41) | TDP1RECQLPOLBTHRBL3MBTL1 | |
| SCHEMBL11437491 | 0.81 | RAPGEF4 (0.42) | TDP1RECQLRAPGEF4LMNASMN1; SMN2 | |
| SCHEMBL7534755 | 0.77 | MAPK14 (0.43) | TDP1POLBSMN1; SMN2GAAMEN1 | |
| SCHEMBL11240997 | 0.77 | CYP1A2 (0.38) | TDP1RECQLPOLBL3MBTL1RAPGEF4 | |
| SCHEMBL10749199 | 0.77 | L3MBTL1 (0.49) | TDP1RECQLPOLBTHRBL3MBTL1 | |
| SCHEMBL10994173 | 0.74 | ALDH1A1 (0.44) | L3MBTL1RAPGEF4GAAALDH1A1NR1I2 | |
| SCHEMBL28457033 | 0.74 | CRHR1 (0.40) | TDP1RECQLPOLBTHRBL3MBTL1 | |
| SCHEMBL7531364 | 0.72 | LMNA (0.58) | TDP1RECQLPOLBTHRBL3MBTL1 | |
| SCHEMBL9829293 | 0.72 | ABCB1 (0.51) | TDP1L3MBTL1ABCB1GAAMEN1 | |
| SCHEMBL3628389 | 0.71 | MAPT (0.34) | LMNAGAACISD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137740-A1 | Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them | FONTAINE EVELYNE (FR) | 2002-09-26 | — | — | US | disclosed |
| EP-0934290-B1 | AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2002-04-17 | — | — | EP | disclosed |
| US-6344470-B1 | Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| EP-0934290-A1 | AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015543-A1 | AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137740-A1 | Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them | CRHR1, ADRA1D, ADRB1 | TDP1 4512/4885RECQL 2307/4885POLB 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.